Loading…
CCCC
C4 Therapeutics, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 12529R107
$3.18+0.32%Price as of Oct 23, 00:54 UTC · updated once a day, after the close
At a glance
C4 Therapeutics, Inc. (CCCC) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Watertown, United States and has 104 employees. The company is worth $391.22M. Revenue was $35.95M in fiscal 2025, up 1.0% from the year before. It reported a net loss of $104.99M. The share price is 38.5% below its 52-week high of $5.17. 5 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Ken Griffin (Citadel Advisors), at $19.56M. In that quarter, 2 of them opened or added to the position and 2 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Key metrics
- Market cap
- $391.22M
- P/E
- —
- Forward P/E
- —
- P/B
- 1.6x
- Dividend yield
- 0.00%
- Payout
- —
- EPS
- -$0.91
- ROE
- -48.14%
- Profit margin
- -289.44%
- Revenue growth
- +2.80%
- Beta
- 3.08
- 52-week high
- $5.17
- 52-week low
- $1.69
History
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Ken GriffinAddedCitadel Advisors · Q2 2026$19.56M4.19M shares · 0.0% of portfolio- Two SigmaAddedTwo Sigma Investments · Q2 2026$16.2M3.47M shares · 0.0% of portfolio
- Renaissance TechnologiesReducedRenaissance Technologies · Q2 2026$5.56M1.19M shares · 0.0% of portfolio
- Israel EnglanderReducedMillennium Management · Q2 2026$1.01M215.39K shares · 0.0% of portfolio
- Steve CohenHeldPoint72 Asset Management · Q2 2026$812.42K173.97K shares · 0.0% of portfolio
Price over time
▼ -92.6% over 5Y.
today you would have $62.25▼ -93.8%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 6 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Year-end price | $1.91 | $3.60 | $5.65 | $5.90 | $32.20 | $33.13 | |
| P/S | 9.3x | 5.2x | 7.2x | 18.7x | 9.3x | 34.3x | — |
| P/B | 1.4x | 0.7x | 1.2x | 1.6x | 1.0x | 4.0x | 5.1x |
| EPS | -$1.27 | -$1.52 | -$2.67 | -$2.62 | -$1.82 | -$5.83 | |
| Profit margin | -295.96% | -292.08% | -295.96% | -638.34% | -412.19% | -183.23% | — |
| ROE | -42.62% | -40.92% | -48.76% | -53.83% | -44.32% | -21.53% | -23.62% |
Median of the years shown; P/E years above 200x are left out.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CAPRCapricor Therapeutics Inc | $6.71 | — | 1.6x | 0.00% | -73.70% | $390.11M |
| EMBCEmbecta Corp. | $6.86 | 4.5x | — | 4.66% | — | $388.68M |
| AUNAAUNA S.a | $5.32 | 88.7x | 0.8x | 0.00% | 1.62% | $393.98M |
| TRXBTRex Bio, Inc. | $14.01 | — | — | 0.00% | — | $384.51M |
| EDITEditas Medicine, Inc. | $2.49 | — | 3.6x | 0.00% | -118.82% | $382.41M |
| SRTAStrata Critical Medical, Inc. | $4.54 | — | 1.4x | 0.00% | -9.22% | $401.64M |
About the company
- 104
- Watertown, United States